A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors
Completed
- Conditions
- Leukemia, Myeloid
- Registration Number
- NCT04598789
- Brief Summary
The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 61
Inclusion Criteria
- children and adults)
- HSCT from a one-antigen mismatch unrelated donors
- Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017
Exclusion Criteria
none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method acute GvHD incidence 2012-2017
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of ATG-CSA-MTX and PTCy-MMF-FK506 in preventing GvHD after HSCT from mismatched unrelated donors in leukemia patients?
How does the use of ATG-CSA-MTX compare to PTCy-MMF-FK506 in terms of acute and chronic GvHD incidence in myeloid leukemia patients undergoing HSCT with mismatched unrelated donors?
Which biomarkers are associated with improved overall survival and reduced transplant-related mortality in patients receiving HSCT from mismatched unrelated donors for myeloid leukemia?
What are the potential adverse events and management strategies for GvHD prophylaxis regimens ATG-CSA-MTX and PTCy-MMF-FK506 in HSCT for myeloid leukemia?
How do ATG-CSA-MTX and PTCy-MMF-FK506 combination approaches compare to other immunosuppressive therapies in HSCT from mismatched unrelated donors for leukemia?
Trial Locations
- Locations (1)
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
🇮🇹Turin, Italy
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita🇮🇹Turin, Italy